Log in
Enquire now
‌

US Patent 10028950 Lanthionine synthetase C-like 2-based therapeutics

Patent 10028950 was granted and assigned to Landos Biopharma on July, 2018 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Patent Applicant
Landos Biopharma
Landos Biopharma
Current Assignee
Landos Biopharma
Landos Biopharma
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
10028950
Date of Patent
July 24, 2018
Patent Application Number
15795906
Date Filed
October 27, 2017
Patent Citations Received
‌
US Patent 11377437 Lanthionine C-like protein 2 ligands, cells prepared therewith, and therapies using same
‌
US Patent 10849895 Lanthionine synthetase C-like 2-based therapeutics
‌
US Patent 11571419 Lanthionine synthetase C-like 2-based therapeutics
‌
US Patent 11492342 Crystalline forms of piperazine-1,4-diylbis((6-(1H-benzo[d]imidazo-2-yl)pyridin-2yl)methanone)
‌
US Patent 10682349 Lanthionine synthetase C-like 2-based therapeutics
Patent Primary Examiner
‌
Emily A Bernhardt
Patent abstract

Provided are compounds that target the lanthionine synthetase C-like protein 2 pathway. The compounds can be used to treat a number of conditions, including infectious disease, autoimmune disease, diabetes, and a chronic inflammatory disease.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 10028950 Lanthionine synthetase C-like 2-based therapeutics

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.